Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LUHUA WANG

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1417042722
CMS profile
245664
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$59,304.61

76 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LUHUA WANG

NPI 1417042722 · CMS profile ID 245664

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417042722?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LUHUA WANG, NPI 1417042722, CMS profile ID 245664. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417042722?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LUHUA WANG, NPI 1417042722, CMS profile ID 245664. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417042722?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LUHUA WANG, NPI 1417042722, CMS profile ID 245664, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1417042722?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

76 matching records · $59,304.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 76 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–76 of 76.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharmacyclics LLC, An AbbVie Company $450.0005/30/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297577 CMS
Pharmacyclics LLC, An AbbVie Company $6,300.0005/30/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297579 CMS
Kite Pharma, Inc. $180.7305/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025274691 CMS
Pharmacyclics LLC, An AbbVie Company $2,250.0005/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297575 CMS
Kite Pharma, Inc. $6,610.0005/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025274673 CMS
Kite Pharma, Inc. $13.1404/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025274677 CMS
Kite Pharma, Inc. $49.9904/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025274679 CMS
Kite Pharma, Inc. $49.9904/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025274681 CMS
Kite Pharma, Inc. $303.9704/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025274687 CMS
Kite Pharma, Inc. $847.8004/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025274689 CMS
Pharmacyclics LLC, An AbbVie Company $8.2304/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297573 CMS
AstraZeneca Pharmaceuticals LP $24.8904/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025051123 CMS
Genmab U.S., Inc. $22.9803/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051346141 CMS
AbbVie Inc. $700.0002/28/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999510503 CMS
Lilly USA, LLC $2,700.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031794905 CMS
Lilly USA, LLC $2,700.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031794909 CMS
AbbVie Inc. $1,400.0002/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999510495 CMS
Eli Lilly and Company $49.8802/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031779991 CMS
Eli Lilly and Company $31.4502/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031907365 CMS
Eli Lilly and Company $55.8402/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031857537 CMS
Lilly USA, LLC $212.2802/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031857541 CMS
Lilly USA, LLC $349.6102/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031857545 CMS
Lilly USA, LLC $179.6202/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031882571 CMS
Lilly USA, LLC $332.8502/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031882575 CMS
E.R. Squibb & Sons, L.L.C. $1,384.0001/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016379463 CMS
Astellas Pharma US Inc $73.9901/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033861471 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40,908.78 49
PY2020 $30,357.87 26
PY2021 $34,909.60 26
PY2022 $56,996.76 47
PY2023 $59,304.61 76
PY2024 $13,354.88 23
PY2025 $11,391.06 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $10,649,794.24 216
PY2024 Principal investigator $12,357,670.29 169
PY2023 Recipient $2,092.78 3
PY2023 Principal investigator $6,815,078.07 227
PY2022 Recipient $43,024.00 2
PY2022 Principal investigator $23,188,500.26 191
PY2021 Principal investigator $17,688,777.12 233
PY2020 Principal investigator $5,790,285.30 178
PY2019 Recipient $4,535.72 3
PY2019 Principal investigator $2,873,856.76 236

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

216 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Kite Pharma, Inc. $633,678.00 12/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) No dispute reported 06/30/2026 1212069069
Principal investigator 1 BeOne Medicines USA, Inc. $12,083.00 12/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190332273
Principal investigator 1 BeOne Medicines USA, Inc. $18,298.00 12/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333214
Principal investigator 1 Eli Lilly and Company $52,392.00 11/20/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
LONG-TERM SAFETY OF PIRTOBRUTINIB IN PARTICIPANTS FROM STUDY LOXO-BTK-18001 WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1187875035
Principal investigator 1 Janssen Research & Development, LLC $160.44 11/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, inParticipants with NHL and CLL No dispute reported 06/30/2026 1175403277
Principal investigator 1 BeOne Medicines USA, Inc. $28,336.00 10/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190332271
Principal investigator 1 Kite Pharma, Inc. $38,250.00 10/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) No dispute reported 06/30/2026 1212069062
Principal investigator 1 BeOne Medicines Ltd. $50,304.00 10/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330437
Principal investigator 1 BeOne Medicines USA, Inc. $44,375.00 10/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190341802
Principal investigator 1 Janssen Research & Development, LLC $118,718.00 10/13/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
PCI-32765MCL3002: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma No dispute reported 06/30/2026 1175403297
Principal investigator 1 BeOne Medicines USA, Inc. $10,567.00 10/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190332275
Principal investigator 1 BeOne Medicines USA, Inc. $17,200.00 09/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333203
Principal investigator 1 BeOne Medicines Ltd. $2,826.01 09/02/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190328567
Principal investigator 1 BeOne Medicines USA, Inc. $12,951.00 09/02/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333210
Principal investigator 1 BeOne Medicines Ltd. $100,608.00 08/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330435
Principal investigator 1 BeOne Medicines USA, Inc. $9,572.00 08/19/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190332269
Principal investigator 1 BeOne Medicines USA, Inc. $72,312.50 08/19/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190343365
Principal investigator 1 BeOne Medicines USA, Inc. $10,115.00 07/29/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333199
Principal investigator 1 Janssen Research & Development, LLC $2,084.34 07/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
PCI-32765MCL3002: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lympho No dispute reported 06/30/2026 1175403030
Principal investigator 1 Kite Pharma, Inc. $16,250.00 07/15/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) No dispute reported 06/30/2026 1212069041
Principal investigator 1 Kite Pharma, Inc. $234,688.00 07/15/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) No dispute reported 06/30/2026 1212069046
Principal investigator 1 Kite Pharma, Inc. $39,473.28 07/15/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) No dispute reported 06/30/2026 1212069054
Principal investigator 1 BeOne Medicines Ltd. $3,125.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327365
Principal investigator 1 BeOne Medicines Ltd. $8,000.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327379
Principal investigator 1 BeOne Medicines Ltd. $50,304.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330405
Principal investigator 1 BeOne Medicines Ltd. $1,993.34 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331821
Principal investigator 1 BeOne Medicines Ltd. $250.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331833
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331837
Principal investigator 1 BeOne Medicines Ltd. $9,375.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343110
Principal investigator 1 BeOne Medicines Ltd. $13,000.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343116
Principal investigator 1 BeOne Medicines Ltd. $3,927.50 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343198
Principal investigator 1 BeOne Medicines Ltd. $5,000.00 07/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343267
Principal investigator 1 BeOne Medicines USA, Inc. $49,395.00 07/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333207
Principal investigator 1 BeOne Medicines USA, Inc. $3,662.35 06/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326670
Principal investigator 1 Incyte Corporation $30,000.00 06/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Not supplied No dispute reported 06/30/2026 1240495306
Principal investigator 1 Incyte Corporation $37,934.04 06/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Not supplied No dispute reported 06/30/2026 1240495310
Principal investigator 1 BeOne Medicines USA, Inc. $1,992.68 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326656
Principal investigator 1 BeOne Medicines USA, Inc. $1,128.34 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326658
Principal investigator 1 BeOne Medicines USA, Inc. $2,489.86 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326660
Principal investigator 1 BeOne Medicines USA, Inc. $1,003.53 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326662
Principal investigator 1 BeOne Medicines USA, Inc. $2,245.16 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326664
Principal investigator 1 BeOne Medicines USA, Inc. $2,617.24 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326666
Principal investigator 1 BeOne Medicines USA, Inc. $870.95 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326668
Principal investigator 1 BeOne Medicines USA, Inc. $313.81 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326672
Principal investigator 1 BeOne Medicines USA, Inc. $957.59 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326674
Principal investigator 1 BeOne Medicines USA, Inc. $1,212.89 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326676
Principal investigator 1 BeOne Medicines USA, Inc. $1,037.26 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326678
Principal investigator 1 BeOne Medicines USA, Inc. $1,226.10 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326680
Principal investigator 1 BeOne Medicines USA, Inc. $766.31 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326682
Principal investigator 1 BeOne Medicines USA, Inc. $6,753.00 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190330993
Principal investigator 1 AstraZeneca Pharmaceuticals LP $949,749.00 05/19/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open Label Phase II Investigator Initiated Study of Venetoclax and Acalabrutinib in previously treated relapsed refractory Patients with Mantle Cell Lymphoma (MCL) No dispute reported 06/30/2026 1185555635
Principal investigator 1 BeOne Medicines USA, Inc. $31,941.00 05/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190330991
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,250.78 05/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185555637
Principal investigator 1 BeOne Medicines USA, Inc. $62,230.00 04/29/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190330989
Principal investigator 1 BeiGene, Ltd. $6,293.01 04/22/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190323038
Principal investigator 1 BeiGene, Ltd. $33,536.00 04/08/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190322300
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $429,271.32 03/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) No dispute reported 06/30/2026 1235999489
Principal investigator 1 Janssen Research & Development, LLC $62,581.36 03/13/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase II Study of Ibrutinib plus Rituximab followed by Venetoclax and Hyper CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma Window II Protocol No dispute reported 06/30/2026 1175403078
Principal investigator 1 BeiGene USA, Inc. $32,138.00 03/04/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190324458
Principal investigator 1 BeiGene USA, Inc. $31,682.00 02/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190324460
Principal investigator 1 ABBVIE INC. $86,098.45 02/20/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202430067
Principal investigator 1 BeiGene, Ltd. $1,122.00 02/14/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320056
Principal investigator 1 BeiGene, Ltd. $997.00 02/14/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324364
Principal investigator 1 Eli Lilly and Company $86,012.10 02/14/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1187879557
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,748,745.00 02/10/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase II Study of Acalabrutinib plus rituximab in previously untreated elderly patients with Mantle Cell Lymphoma No dispute reported 06/30/2026 1185555643
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,668.00 01/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents No dispute reported 06/30/2026 1185555645
Principal investigator 1 BeiGene USA, Inc. $2,093.75 01/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190320286
Principal investigator 1 BeiGene USA, Inc. $2,815.59 01/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190320288
Principal investigator 1 BeiGene USA, Inc. $303.29 01/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190320290
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429264
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429267
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429270
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429274
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429277
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429282
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429286
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429290
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429295
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429298
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429302
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429305
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429309
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429311
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429314
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429320
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429325
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429329
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429334
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429337
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429342
Principal investigator 1 ABBVIE INC. $42,808.19 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429346
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429349
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429353
Principal investigator 1 ABBVIE INC. $2,484.75 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429358
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429362
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429366
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429369
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429373
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429377
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429381
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429385
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429390
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429393
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429398
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429402
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429406
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429411
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429415
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429419
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429423
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429427
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429431
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429436
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429440
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429443
Principal investigator 1 ABBVIE INC. $2,484.75 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429447
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429450
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429454
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429457
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429461
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429466
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429470
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429475
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429479
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429482
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429487
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429490
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429493
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429497
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429501
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429506
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429511
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429516
Principal investigator 1 ABBVIE INC. $2,484.75 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429519
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429524
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429529
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429533
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429537
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429541
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429544
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429547
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429551
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429555
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429559
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429563
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429567
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429571
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429574
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429578
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429582
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429586
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429590
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429593
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429598
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429602
Principal investigator 1 ABBVIE INC. $2,484.75 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429605
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429609
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429613
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429617
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429622
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429626
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429631
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429635
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429639
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429643
Principal investigator 1 ABBVIE INC. $2,484.75 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429647
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429652
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429657
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429661
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429664
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429669
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429673
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429676
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429680
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429683
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429687
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429691
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429694
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429699
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429702
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429707
Principal investigator 1 ABBVIE INC. $2,484.75 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429711
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429716
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429719
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429724
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429727
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429731
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429735
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429739
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429744
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429749
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429753
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429756
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429760
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429765
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429769
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429774
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429778
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429781
Principal investigator 1 ABBVIE INC. $2,001.84 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429785
Principal investigator 1 ABBVIE INC. $2,305.95 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429790
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429794
Principal investigator 1 ABBVIE INC. $1,476.45 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429798
Principal investigator 1 ABBVIE INC. $2,484.75 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429802
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429806
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429811
Principal investigator 1 ABBVIE INC. $2,769.55 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429813
Principal investigator 1 ABBVIE INC. $1,510.20 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429818
Principal investigator 1 ABBVIE INC. $3,602.83 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429821
Principal investigator 1 ABBVIE INC. $1,391.73 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) No dispute reported 06/30/2026 1202429827
Principal investigator 1 Eli Lilly and Company $2,103.78 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1187875149
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,823,144.62 01/24/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naive Mantle Cell Lymphoma No dispute reported 06/30/2026 1185555639
Principal investigator 1 Eli Lilly and Company $2,178.65 01/09/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187879559
Principal investigator 1 Acerta Pharma LLC $43,958.87 01/08/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185555641
Principal investigator 1 Eli Lilly and Company $77,129.94 01/08/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187873595
Principal investigator 1 Janssen Research & Development, LLC $13,884.57 01/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase II Study of Ibrutinib plus Rituximab followed by Venetoclax and Hyper CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma Window II Protocol No dispute reported 06/30/2026 1175402957